Skip to main content

Table 2 Chemotherapy

From: Efficacy, safety and feasibility of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients receiving moderately and highly emetogenic chemotherapy – results of a non-interventional observation study

 DosageEPFosaprepitant groupControl groupp-value
   N = 112 coursesN = 116 courses
   n (%)n (%)
Agent
 Carboplatin 48 (7.1)8 (6.9)> 0.9999
 Cisplatin 45 (4.5)8 (6.9)0.5704
 Clofarabine 30 (0.0)1 (0.9)> 0.9999
 Cyclophosphamide≥1 g/m242 (1.8)2 (1.7)> 0.9999
 Cyclophosphamide< 1 g/m2319 (17.0)18 (15.5)0.9072
 Cytarabine> 200 mg/m2 to < 3 g/ m2316 (14.3)11 (9.5)0.3591
 Dacarbazine 43 (2.7)2 (1.7)0.6793
 Dactinomycin 49 (8.0)7 (6.0)0.6112
 Daunorubicin 34 (3.6)10 (8.6)0.1669
 Doxorubicin 316 (14.3)10 (8.6)0.2555
 Epirubicin 32 (1.8)0 (0.0)0.2402
 Etoposide 328 (25.0)25 (21.6)0.6459
 Idarubicin 31 (0.9)0 (0.0)0.4912
 Ifosfamide 317 (15.2)12 (10.3)0.3701
 Irinotecan 30 (0.0)2 (1.7)0.498
 Melphalan> 50 mg/m231 (0.9)1 (0.9)1.0000
 Methotrexate≥250 mg to < 12 g/m2320 (17.9)15 (12.9)0.3965
 Temozolomide 30 (0.0)1 (0.9)> 0.9999
 Thiotepa≥300 mg/m241 (0.9)0 (0.0)0.4912
 EP (CINV risk)
  3 (> 30–90%) 84 (75.0)89 (76.7)0.8812
  4 (> 90%) 28 (25.0)27 (23.3) 
  1. The table shows the emetogenic potential (EP) of the administered chemotherapeutic agents in the fosaprepitant and the control group. EP was defined by the emetic risk (in % frequency of emesis in absence of prophylaxis): minimal, stage 1 (< 10%) | low, stage 2 (10 - < 30%) | moderate, stage 3 (30–90%) | high, stage 4 (> 90%) [9]
  2. Abbreviations: CINV chemotherapy-induced nausea and vomiting, EP emetogenic potential, N total number of administered chemotherapy courses, n sample size. The distribution of administered chemotherapeutic agents and the highest emetogenic potential of each chemotherapy course was not significantly different in both cohorts (p > 0.05; Chi-square test with Yate’s correction or Fisher’s exact test)